PRS9 COST-EFFECTIVENESS MODEL OF MOXIFLOXACIN IN ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS (AECB) IN GERMANY INCLUDING THE EFFECTS OF RESISTANCE
Nov 1, 2008, 00:00
10.1016/S1098-3015(10)66507-2
https://www.valueinhealthjournal.com/article/S1098-3015(10)66507-2/fulltext
Title :
PRS9 COST-EFFECTIVENESS MODEL OF MOXIFLOXACIN IN ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS (AECB) IN GERMANY INCLUDING THE EFFECTS OF RESISTANCE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)66507-2&doi=10.1016/S1098-3015(10)66507-2
First page :
Section Title :
Open access? :
No
Section Order :
342